MedTrace Logo

CBD in Postmenopausal Women With Osteopenia

NCT05317013 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-09-23

No results posted yet for this study

Summary

This is a Phase 1, double-blind, placebo-controlled, repeated-dose study to assess the safety, tolerability, and preliminary effects of CHI-554 in postmenopausal women ages 50-80 years who have osteopenia.

Conditions

  • Osteopenia

Interventions

DRUG

CBD

CBD

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • NM Clinical Research & Osteoporosis Center, Inc.

    collaborator UNKNOWN

  • Canopy Growth Corporation

    lead INDUSTRY

Principal Investigators

  • Lance Rudolph, MD · NM Clinical Research & Osteoporosis Center, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-09-22
Completion
2022-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05317013 on ClinicalTrials.gov